A prospective, multicentre, randmoised phase III study to evaluate the efficacy of ZOMETA [zoledronic acid] in preventing or delaying bone metastasis in patients with non-small cell lung cancer
Phase of Trial: Phase III
Latest Information Update: 15 Mar 2006
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Cancer metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Mar 2006 New trial record.